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Human pituitary tumor-transforming gene-1 (hPTTG1) is an oncogene that is expressed at a high level in
most tumors, especially in metastatic ones. Accumulating evidence reveals that hPTTG1 is a trancription
factor that has transcriptional activity either by directly or indirectly binding to DNA. Furthermore,
hPTTG1 has been identiﬁed to regulate Rho guanine nucleotide exchange factor-H1 (GEF-H1) directly, by
an interaction with microtubules and contributes to cancer progression. GEF-H1 activity is important for
RhoA-dependent changes in cell morphology and actin organization. hPTTG1 activates GEF-H1/RhoA
signaling to affect cytoskeleton organization, cell motility, cell invasion, and breast cancer metastasis.
Thus, hPTTG1 links changes in microtubule integrity to RhoA-dependent regulation of the actin cyto-
skeleton, and therefore promotes cancer metastasis. The molecular mechanism that links microtubule
dynamics to RhoA-GTPases has not, as yet, been elucidated.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Human pituitary tumor-transforming gene 1 (hPTTG1), origi-
nally isolated from a rat pituitary tumor GH4 cell cDNA library [1],
has subsequently been identiﬁed as a human securin [2] and is
amultifunctional protein. In cell cycle progression, hPTTG1 controls
sister chromatid separation during mitosis [3,4]. However, hPTTG1
also behaves as an oncogene whose overexpression transforms
ﬁbroblasts in vitro and enhances tumorigenesis in vivo. As assessed
by anchorage-independent growth in soft agar, hPTTG1-transfected
NIH3T3 and human embryonic kidney (HEK)293 cells formedmuch
larger colonies compared with control vector-transfected cells
[1,5e7]. Consistent with these results, H1299 lung carcinoma cells
targeted with hPTTG1 small interfering RNA formed smaller colo-
nies in soft agar [8]. In vivo, hPTTG1-transfected NIH3T3 or HEK293
cells formed tumors when these cells were injected into nude mice
[1,5,7,9]. In several clinical studies, hPTTG1 overexpression has
been observed in a wide variety of endocrine and nonendocrine
tumors, including those in the pituitary, thyroid, ovary, breast,
prostate, lung, esophagus, colon, and central nervous system. Inar and Genomic Medicine,
ad, Zhunan, Miaoli, Taiwan.
ddhist Compassion Relief Tzu Chiaddition, hPTTG1 overexpression is considered a potential invasive
marker that is relevant to the malignancy of breast cancer [10].
When analyzing hPTTG1 mRNA expression in 72 primary tumors
from patients, a direct correlation was found between hPTTG1
mRNA overexpression and lymph node inﬁltration [11]. In addition,
overexpression of hPTTG1 in breast tumors correlates with a higher
degree of tumor recurrence. Taken together, the determination of
hPTTG1 expression in primary breast tumors is a powerful tool for
the assessment of potential tumor aggressiveness [11]. Tumors that
express high levels of hPTTG1 mRNA also exhibit high levels of
expression of basic ﬁbroblast growth factor (bFGF), suggesting
a correlation between hPTTG1 and bFGF expression, and further
suggesting that the hPTTG1 protein may be involved in tumor
angiogenesis and mitogenesis [12]. In this review, we describe how
hPTTG1 serves as a transcription factor, and its role in directly
regulating the GEF-H1 gene and promoting metastasis.2. hPTTG1 and transcriptional activity
hPTTG1 has one N-terminal basic domain and one C-terminal
acidic domain. The C-terminal region of hPTTG1 was found to
possess transactivation activity when fused to a heterologous DNA-
binding domain [13]. Thus hPTTG1 has been characterized as
a transcription factor that regulates the expression of genes
involved in a variety of cellular processes [14]. It appears thatFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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its target genes.
hPTTG1, a transcription factor, can activate several genes such as
c-Myc, FGF2, cyclin D3, p21, the sodium-iodine symporter,
prolactin, and matrix metalloproteinase-2 (MMP2) [15,16]. This
indicates that the transcriptional activity of hPTTG1 may play
important roles in a variety of cellular processes. For example,
hPTTG1 mediates p21-induced cell senescence and subsequently
constrains pituitary tumor development [17]. Several oncogenic
transcription factors can promote malignant progression by
induction of downstream effectors [18,19]. This concept provides
a more plausible explanation of why hPTTG1 is expressed at a high
level in most malignant breast cancers.
It was hypothesized that hPTTG1 exerts its metastasis-
promoting functions by acting as a transcriptional activator for
genes involved in the metastatic process, and found that hPTTG1
directly regulated the transcription of GEF-H1 through hPTTG1-
binding element 1 (TTaACT) on the GEF-H1 regulatory sequence
[20]. GEF-H1 is an oncoprotein that speciﬁcally activates RhoA [21],
a well-known member of the Rho family of guanosine triphos-
phatases (GTPases). Activated RhoA mediates multiple signals that
are involved in cytoskeleton organization, cell motility, cell inva-
sion and cell proliferation [22e25]. All of these events contribute to
tumor metastasis [26,27].
Furthermore, it is well known that gene regulation can not be
determined by only one transcription factor. Thus, an upstream
stimulatory factor 1 (USF1) binding motif was found adjacent to
hPTTG1-binding element 1. USF1 is the ubiquitous basic helix-loop-
helix-leucine zipper transcription factor [28]. From reporter assays,
it was veriﬁed that USF1 was not required for GEF-H1 transcription
with or without hPTTG1. Instead, C/EBP alpha transcription factor
may also be a positive regulator for the GEF-H1 gene. C/EBP alpha is
a typical basic region-leucine zipper transcription factor [29]. It is
expressed at a high level not only in the placenta, lung, colon, and
peripheral blood leukocytes but also more frequently in adeno-
carcinoma cells [30,31]. Thus, C/EBP alpha may contribute to the
development of malignancies in a variety of tissues. C/EBP alpha is
a transcription factor strongly implicated in myelopoiesis through
control of proliferation and differentiation of myeloid progenitors.
Recently, several studies have reported the presence of C/EBP
alpha-acquired mutations in hematological malignancies [32e34].
Data from reporter assays show that hPTTG1 and C/EBP alpha
cooperates to control the activities of the GEF-H1 gene. This indi-
cates that C/EBP alpha may be a coactivator of hPTTG1 for GEF-H1
upregulation in metastatic cancer cells, but this notion should be
further investigated.
3. A novel mechanism of breast cancer metastasis
Although there is evidence implicating hPTTG1 in the regulation
Myc, MMP2, p21 and p53, how hPTTG1 promotes tumor growth
and metastasis through these downstream genes is not clear.
Multiple molecular events participate in tumor growth and the
metastasis process. It is likely that hPTTG1 regulates different
tumor developmental events by different downstream genes. The
authors’ group was the ﬁrst, as far as we know, to identify that
hPTTG1 can regulate cytoskeletal dynamics through RhoA-GTP
activation [20].
RhoA-GTPase is expressed ubiquitously in different human
tissues [35]. One important issue in cancer biology is how RhoA-
GTPase is activated pathologically. GEF-H1 is the major molecule
that regulates the activity of RhoA physiologically. GEF-H1 activity
is regulated bymicrotubule binding [36] andmicrotubule dynamics
that speciﬁcally connect cellular RhoA activation and actin cyto-
skeleton regulation [37]. Consistent with the fact that GEF-H1mediates RhoA-dependent F-actin stress ﬁber formation [38,39],
results showed that hPTTG1-induced GEF-H1 expression increases
the amount of GTP-bound RhoA, thereby increasing the assembly of
F-actin stress ﬁbers and focal adhesions in breast cancer cells [20].
GEF-H1 has been proposed to play a role in regulating the meta-
static capacities of cancer cells because its regulatory effects on the
actin cytoskeleton are likely to enhance the migratory and invasive
properties of cancer cells [37]. This speculation is supported by
observation of the newly discovered role of hPTTG1/GEF-H1/RhoA
signaling in cytoskeleton regulation, which is one of the driving
forces in breast cancer metastasis [20].
It is important to emphasize the newly discovered role of
hPTTG1 in cytoskeleton control, which is probably pathologically
relevant to the potential of tumor cell migration and invasion.
Consistent with in vitro ﬁndings, in vivo results demonstrated the
importance of hPTTG1/GEF-H1 signaling in driving breast cancer
metastasis [20]. In a tail vein metastasis mouse model, it was
found that hPTTG1-knockdown MDA-MB-231 cells with GEF-H1
restoration regained their metastatic properties and behaved
like wild-type MDA-MB-231 cells. By 10 weeks after tail vein
injection, MDA-MB-231 cells in which hPTTG1 was endogenously
overexpressed had more metastatic ability (six of six mice
developed metastases) than hPTTG1 ectopically overexpressed
MCF-7 cells (one of six mice developed metastases; no metastases
developed with MCF-7 cells). Perhaps, longer monitoring times
are needed to observe these secondary tumors. Therefore, MCF-7
cells (control vector or pcDNA3-hPTTG1) were orthotopically
injected into mammary fat pads and it was found that 16 to 18
weeks after injection, hPTTG1-overexpressed MCF-7 cells, but not
control MCF-7 cells, formed many large tumor nodules in the lung
and pleura [20]. The results indicated that overexpressed hPTTG1
in MCF-7 cells requires a longer time to form tumor metastases
compared with MDA-MB-231 cells, which can form tumor
metastasis within 10 weeks after injection. Because tumor
metastasis is a complicated process that involves, for instance,
activated oncogenes and mutated tumor suppressor genes [40],
hPTTG1 may need to cooperate with other oncogenic factors to
drive metastatic processes in nonmetastatic MCF-7 cells. One
possible cofactor for hPTTG1 to drive tumor metastasis is p53
because MDA-MB-231 cells have mutated p53 (R280 K) [41], and
MCF-7 cells have wild-type p53 [42]. hPTTG1 has been reported to
regulate the transactivation activity of p53 [43]. However, the
possible cooperation of overexpressed hPTTG1 and mutated p53
in metastatic progression requires further investigation.
4. The clinical importance of hPTTG1 and GEF-H1 protein in
invasive breast carcinoma
Breast tumors are currently evaluated on the basis of several
histopathological features including size, grade, and lymph node
status, all of which contribute to assessing the overall stage of
cancer development. In addition, hormone receptors (estrogen
receptor, progesterone receptor) and human epidermal growth
factor receptor 2 expression in tumors, together with the histo-
pathological features, are used to classify the progression of the
disease and thus currently provide a rational basis for the aggres-
siveness of treatment.
Ogbagabriel et al proposed that increased hPTTG1 is a marker of
breast tumor proliferative capacity and may aid in the detection of
cancers more likely to follow an aggressive clinical course, and
identiﬁcation of patients more likely to beneﬁt from adjuvant
therapies [10]. It has been demonstrated that low cytoplasmic
hPTTG1 expression in normal breast epithelium, whereas abundant
nuclear hPTTG1 expressionwas demonstrated in almost all invasive
breast tumor samples (68 out of 70) [20]. Furthermore, abundant
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tumor samples (65 out of 70). hPTTG1 and GEF-H1 overexpression
are positively correlated with each other in invasive breast tumor
samples. In addition to hPTTG1, GEF-H1 also represents a potential
novel marker of breast cancer. Analysis of hPTTG1 and GEF-H1
expression in breast cancer may provide important prognostic
insights and portend the response to treatment in breast cancer.5. Summary
The role of overexpressed hPTTG1 has been identiﬁed in regu-
lating breast cancer metastasis [20]. hPTTG1 directly regulates GEF-
H1 gene transcription and RhoA activation in breast cancer cells.
Additionaly, it has been demonstrated that activation of hPTTG1/
GEF-H1 signaling is essential for breast cancer cell migration and
invasion, and is required for actin cytoskeleton rearrangement
upon RhoA activation. In vivo evidence has shown that hPTTG1/
GEF-H1 signaling is required for breast cancer metastasis in
a mouse model. Finally, clinical observations showed a positive
correlation between hPTTG1 and GEF-H1 expression in human
invasive breast cancers. This work has revealed that hPTTG1 acti-
vates GEF-H1 as a novel mechanism to regulate breast cancer
metastasis via RhoA signaling.
Importantly, there is new insight into how hPTTG1 promotes
breast cancer metastasis. Results showed that overexpressed
hPTTG1 directly activates GEF-H1, which in turn, activates RhoA,
a regulator of actin organisation. hPTTG1 enhances the migratory
and invasive ability of tumor cells through RhoA activation. Thus,
hPTTG1 is an attractive therapeutic target in treating metastatic
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